Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1969 Jun;48(6):1033–1040. doi: 10.1172/JCI106059

Localization of the oxidative defect in phytanic acid degradation in patients with refsum's disease

Charles E Mize 1, James H Herndon Jr 1, John P Blass 1, G W A Milne 1, Charlotte Follansbee 1, Philippe Laudat 1, Daniel Steinberg 1
PMCID: PMC322317  PMID: 4181594

Abstract

The rate of oxidation of phytanic acid-U-14C to 14CO2 in three patients with Refsum's disease was less than 5% of that found in normal volunteers. In contrast, the rate of oxidation of α-hydroxyphytanic acid-U-14C and of pristanic acid-U-14C to 14CO2, studied in two patients, while somewhat less than that in normal controls, was not grossly impaired. These studies support the conclusion that the defect in phytanic acid oxidation in Refsum's disease is located in the first step of phytanic acid degradation, that is, in the alpha oxidation step leading to formation of α-hydroxyphytanic acid.

The initial rate of disappearance of plasma free fatty acid radioactivity after intravenous injection of phytanic acid-U-14C (t½ = 5.9 min) was slower than that seen with pristanic acid-U-14C (t½ = 2.7 min) or palmitic acid-1-14C (t½ = 2.5 min). There were no differences between patients and normal controls in these initial rates of free fatty acid disappearance for any of the three substrates tested.

There was no detectable lipid radioactivity found in the plasma 7 days after the injection of palmitic acid-1-14C or pristanic acid-U-14C in either patients or controls. After injection of phytanic acid-U-14C, however, the two patients showed only a very slow decline in plasma lipid radioactivity (estimated t½ = 35 days), in contrast to the normals who had no detectable radioactivity after 2 days. Incorporation of radioactivity from phytanic acid-U-14C into the major lipid ester classes of plasma was studied in one of the patients; triglycerides accounted for by far the largest fraction of the total present between 1 and 4 hr.

Full text

PDF
1033

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ASHENHURST E. M., MILLAR J. H., MILLIKEN T. G. Refsum's syndrome affecting a brother and two sisters. Br Med J. 1958 Aug 16;2(5093):415–417. doi: 10.1136/bmj.2.5093.415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Avigan J., Steinberg D., Gutman A., Mize C. E., Milne G. W. Alpha-decarboxylation, an important pathway for degradation of phytanic acid in animals. Biochem Biophys Res Commun. 1966 Sep 22;24(6):838–844. doi: 10.1016/0006-291x(66)90324-x. [DOI] [PubMed] [Google Scholar]
  3. Baxter J. H., Steinberg D., Mize C. E., Avigan J. Absorption and metabolism of uniformly 14C-labeled phytol and phytanic acid by the intestine of the rat studied with thoracic duct cannulation. Biochim Biophys Acta. 1967 Apr 4;137(2):277–290. doi: 10.1016/0005-2760(67)90103-8. [DOI] [PubMed] [Google Scholar]
  4. Bonduelle M., Bouygues P., Lormeau G., Deloux G., Laudat P., Wolf L. M. Maladie de Refsum. Etude des lipides du sérum et des urines. Rev Neurol (Paris) 1966 Nov;115(5):933–942. [PubMed] [Google Scholar]
  5. ELDJARN L. HEREDOPATHIA ATACTICA POLYNEURITIFORMIS (REFSUM'S DISEASE)--A DEFECT IN THE OMEGA-OXIDATION MECHANISM OF FATTY ACIDS. Scand J Clin Lab Invest. 1965;17:178–181. doi: 10.1080/00365516509077305. [DOI] [PubMed] [Google Scholar]
  6. Eldjarn L., Stokke O., Try K. Alpha-oxidation of branched chain fatty acids in man and its failure in patients with Refsum's disease showing phytanic acid accumulation. Scand J Clin Lab Invest. 1966;18(6):694–695. doi: 10.3109/00365516609049057. [DOI] [PubMed] [Google Scholar]
  7. Eldjarn L., Try K., Stokke O., Munthe-Kaas A. W., Refsum S., Steinberg D., Avigan J., Mize C. Dietary effects on serum-phytanic-acid levels and on clinical manifestations in heredopathia atactica polyneuritiformis. Lancet. 1966 Mar 26;1(7439):691–693. doi: 10.1016/s0140-6736(66)91632-1. [DOI] [PubMed] [Google Scholar]
  8. Eldjarn L., Try K., Stokke O. The ability of patients with herdopathia atactica polyneuritiformis to alpha-oxidize and degrade several isoprenoid branch-chained fatty structures. Scand J Clin Lab Invest. 1966;18(2):141–150. doi: 10.3109/00365516609051810. [DOI] [PubMed] [Google Scholar]
  9. Eldjarn L., Try K., Stokke O. The existence of an alternative pathway for the degradation of branch-chained fatty acids, and its failure in heredopathia atactica polyneuritiformis (Refsum's disease). Biochim Biophys Acta. 1966 Apr 4;116(2):395–397. doi: 10.1016/0005-2760(66)90023-3. [DOI] [PubMed] [Google Scholar]
  10. Hansen R. P. 3,7,11,15-tetramethylhexadecanoic acid: its occurrence in the tissues of humans afflicted with Refsum's syndrome. Biochim Biophys Acta. 1965 Oct 4;106(2):304–310. doi: 10.1016/0005-2760(65)90038-x. [DOI] [PubMed] [Google Scholar]
  11. Hansen R. P., Shorland F. B., Prior I. A. The fate of phytanic acid when administered to rats. Biochim Biophys Acta. 1966 Feb 1;116(1):178–180. doi: 10.1016/0005-2760(66)90108-1. [DOI] [PubMed] [Google Scholar]
  12. Herndon J. H., Jr, Steinberg D., Uhlendorf B. W., Fales H. M. Refsum's disease: characterization of the enzyme defect in cell culture. J Clin Invest. 1969 Jun;48(6):1017–1032. doi: 10.1172/JCI106058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. KAHLKE W. REFSUM-SYNDROM.--LIPOIDCHEMISCHE UNTERSUCHUNGEN BEI 9 FAELLEN. Klin Wochenschr. 1964 Oct 15;42:1011–1016. doi: 10.1007/BF01479444. [DOI] [PubMed] [Google Scholar]
  14. KLENK E., KAHIKE W. UBER DAS VORKOMMEN DER 3.7.11.15-TETRAMETHYL-HEXADECANSAEURE (PHYTANSAEURE) IN DEN CHOLESTERINESTERN UND ANDEREN LIPOIDFRAKTIONEN DER ORGANE BEI EINEM KRANKHEITSFALL UN- BEKANNTER GENESE (VERDACHT AUF HEREDOPATHIA ATACTICA POLYNEURITIFORMIS. Hoppe Seylers Z Physiol Chem. 1963;333:133–139. doi: 10.1515/bchm2.1963.333.1.133. [DOI] [PubMed] [Google Scholar]
  15. KOLODNY E. H., HASS W. K., LANE B., DRUCKER W. D. REFSUM'S SYNDROME: REPORT OF A CASE INCLUDING ELECTRON MICROSCOPIC STUDIES OF THE LIVER. Arch Neurol. 1965 Jun;12:583–596. doi: 10.1001/archneur.1965.00460300031004. [DOI] [PubMed] [Google Scholar]
  16. Mize C. E., Avigan J., Baxter J. H., Fales H. M., Steinberg D. Metabolism of phytol-U-14C and phytanic acid-U-14C in the rat. J Lipid Res. 1966 Sep;7(5):692–697. [PubMed] [Google Scholar]
  17. Mize C. E., Steinberg D., Avigan J., Fales H. M. A pathway for oxidative degradation of phytanic acid in mammals. Biochem Biophys Res Commun. 1966 Nov 11;25(3):359–365. doi: 10.1016/0006-291x(66)90786-8. [DOI] [PubMed] [Google Scholar]
  18. Richterich R., Moser H., Rossi E. Refsum's disease (heredopathia atactica polyneuritiformis). An inborn error of lipid metabolism with storage of 3,7,11,15 tetramethyl hexadecanoic acid. A review of the clinical findings. Humangenetik. 1965;1(4):322–332. doi: 10.1007/BF00273974. [DOI] [PubMed] [Google Scholar]
  19. Steinberg D., Avigan J., Mize C. E., Baxter J. H., Cammermeyer J., Fales H. M., Highet P. F. Effects of dietary phytol and phytanic acid in animals. J Lipid Res. 1966 Sep;7(5):684–691. [PubMed] [Google Scholar]
  20. Steinberg D., Avigan J., Mize C., Eldjarn L., Try K., Refsum S. Conversion of U-C14-phytol to phytanic acid and its oxidation in heredopathia atactica polyneuritiformis. Biochem Biophys Res Commun. 1965 Jun 9;19(6):783–789. doi: 10.1016/0006-291x(65)90328-1. [DOI] [PubMed] [Google Scholar]
  21. Steinberg D., Herndon J. H., Jr, Uhlendorf B. W., Mize C. E., Avigan J., Milne G. W. Refsum's disease: nature of the enzyme defect. Science. 1967 Jun 30;156(3783):1740–1742. doi: 10.1126/science.156.3783.1740. [DOI] [PubMed] [Google Scholar]
  22. Steinberg D., Mize C. E., Avigan J., Fales H. M., Eldjarn L., Try K., Stokke O., Refsum S. Studies on the metabolic error in Refsum's disease. J Clin Invest. 1967 Mar;46(3):313–322. doi: 10.1172/JCI105533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Steinberg D., Vroom F. Q., Engel W. K., Cammermeyer J., Mize C. E., Avigan J. Refsum's disease--a recently characterized lipidosis involving the nervous system. Combined clinical staff conference at the National Institutes of Health. Ann Intern Med. 1967 Feb;66(2):365–395. doi: 10.7326/0003-4819-66-2-365. [DOI] [PubMed] [Google Scholar]
  24. Stokke O. Alpha-oxidation of a beta-methyl-substituted fatty acid in guinea-pig liver mitochondria. Biochim Biophys Acta. 1968 Jan 10;152(1):213–216. doi: 10.1016/0005-2760(68)90024-6. [DOI] [PubMed] [Google Scholar]
  25. Stokke O., Try K., Eldjarn L. Alpha-oxidation as an alternative pathway for the degradation of branched-chain fatty acids in man, and its failure in patients with Refsum's disease. Biochim Biophys Acta. 1967 Oct 2;144(2):271–284. doi: 10.1016/0005-2760(67)90157-9. [DOI] [PubMed] [Google Scholar]
  26. Tsai S. C., Herndon J. H., Jr, Uhlendorf B. W., Fales H. M., Mize C. E. The formation of alpha-hydroxy phytanic acid from phytanic acid in mammalian tissues. Biochem Biophys Res Commun. 1967 Aug 23;28(4):571–577. doi: 10.1016/0006-291x(67)90352-x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES